Import from '@womanrx/components'

Intrarosa in Your 30s: Is Vaginal DHEA Right for You at This Life Stage?

What Is Intrarosa and How Does It Work?

Prasterone (brand name Intrarosa) is a synthetic form of dehydroepiandrosterone (DHEA) delivered as a 6.5 mg vaginal insert used once nightly. The FDA approved it in November 2016 for moderate-to-severe dyspareunia, a symptom of vulvovaginal atrophy (VVA), in postmenopausal women.

Unlike systemic estrogen or even low-dose vaginal estrogen, prasterone works as a prohormone. Vaginal epithelial cells convert DHEA locally into both estrogens and androgens through intracrinology, the process by which a cell produces sex steroids for its own use rather than releasing them into circulation. This local conversion restores vaginal tissue health: epithelial cell layers thicken, vaginal pH drops toward its premenopausal range, and lubrication improves.

Why Vaginal Tissue Needs Estrogen and Androgen

The vaginal epithelium contains receptors for both estrogens (ERα, ERβ) and androgens (AR). When circulating estradiol falls, whether from menopause, surgical oophorectomy, or medication-induced suppression, the epithelium thins, glycogen content drops, and lactobacillus populations decline. Research published in Menopause confirmed that prasterone 6.5 mg nightly over 12 weeks significantly improved the most bothersome symptom score compared to placebo in postmenopausal women, with a mean difference of approximately 0.36 points on a 3-point scale. Small effect, yes, but consistent and statistically significant across the AMELIA and Prasterone Phase 3 trial programs.

The Intracrinology Distinction

The manufacturer and independent researchers point out that systemic estradiol and testosterone levels, though they do rise slightly after nightly insertion, remain within or near the postmenopausal reference range in the studied population. Labrie et al., writing in the Journal of Steroid Biochemistry and Molecular Biology, showed that serum estradiol after 12 weeks of 6.5 mg prasterone nightly rose from roughly 3 pg/mL to approximately 5 pg/mL, still below the lower limit of a typical premenopausal follicular-phase level of 30-400 pg/mL. This is the pharmacological rationale for calling prasterone a "local" treatment, though the caveat below about younger women matters enormously.

Who Is Actually Using Intrarosa in Their 30s?

Most women in their 30s have fully functional ovaries producing estradiol in the range of 30-300 pg/mL across the menstrual cycle. They do not have vulvovaginal atrophy from estrogen deficiency. Vaginal dryness in this decade almost always has a different cause, and treating it with Intrarosa would be using an FDA-approved menopause drug outside its studied population.

Certain clinical situations create a physiologically postmenopausal vaginal environment in a 30-something woman:

Premature Ovarian Insufficiency

Premature ovarian insufficiency (POI) affects approximately 1% of women under age 40, according to ACOG Committee Opinion 605. These women experience estrogen levels comparable to natural menopause and develop VVA on the same timeline. Prasterone has not been studied specifically in POI, but clinicians may consider it when systemic hormone therapy is insufficient or not tolerated for local symptoms.

Surgical Menopause

Women who undergo bilateral oophorectomy in their 30s, whether for endometriosis, BRCA1/2 risk reduction, or other indications, experience an immediate, abrupt drop in estradiol and DHEA-S. This is physiologically more severe than natural menopause because the transition is instantaneous rather than gradual. VVA can begin within months. Off-label use of prasterone in this setting is clinically defensible, though direct trial data in surgically menopausal women under 40 remains thin.

GnRH Agonist or Antagonist Therapy

Women in their 30s with endometriosis or uterine fibroids are frequently prescribed GnRH agonists (leuprolide, goserelin) or antagonists (elagolix, relugolix). These agents suppress ovarian estrogen production to near-postmenopausal levels. Elagolix, for example, produces a dose-dependent reduction in estradiol that causes VVA symptoms in a significant proportion of users. Add-back estrogen is the standard approach, but for women who cannot use systemic estrogen, a vaginal option becomes relevant.

Chemotherapy-Induced Ovarian Insufficiency

Alkylating agents, platinum compounds, and high-dose cyclophosphamide used in breast cancer, lymphoma, or autoimmune disease treatment can permanently or temporarily suppress ovarian function. A 35-year-old finishing chemotherapy may have FSH levels above 40 mIU/mL and estradiol below 20 pg/mL. For breast cancer survivors, systemic estrogen is often contraindicated, making locally acting options like prasterone worth discussing, although the safety data in hormone-receptor-positive breast cancer survivors is incomplete and requires shared decision-making with the oncologist.

What Causes Vaginal Dryness in Hormonally Intact Women in Their 30s?

Before any clinician prescribes Intrarosa to a woman in her 30s with normal ovarian function, these causes must be systematically excluded:

• Hormonal contraception: Combined oral contraceptives reduce free testosterone and can lower vaginal lubrication in some users. Switching formulation or method often resolves symptoms.
• PCOS and androgen excess: Counterintuitively, androgen excess in PCOS is not associated with VVA, but irregular cycles and anovulation can produce relative estrogen insufficiency in some phases.
• Postpartum and lactation: Breastfeeding suppresses estradiol via prolactin-mediated inhibition of GnRH. Postpartum VVA is common, self-limited in most cases, and responds to topical moisturizers or low-dose vaginal estrogen.
• Sjögren syndrome and autoimmune conditions: Glandular involvement reduces all mucosal secretions, including vaginal.
• Antidepressants (SSRIs/SNRIs): These reduce nitric oxide-mediated arousal and lubrication independent of estrogen status. A 2020 review in the Journal of Sexual Medicine identified SSRI use as a clinically significant contributor to sexual dysfunction and dryness in women of reproductive age.
• Thyroid dysfunction: Both hypothyroidism and hyperthyroidism alter vaginal mucosal health and sexual function. TSH should be checked before attributing dryness to estrogen deficiency.

Treating any of these with prasterone would miss the actual cause and expose the patient to a drug with no evidence of benefit in her physiological situation.

Sex-Specific Pharmacology: What Happens to Prasterone in a Younger Woman's Body?

This is where the evidence gap becomes clinically significant, and you deserve honesty about it.

All pharmacokinetic data for prasterone vaginal inserts comes from postmenopausal women. No published randomized controlled trial has enrolled premenopausal women. The modest serum estradiol and testosterone rises observed after nightly 6.5 mg insertion are described as "within postmenopausal range" specifically because the study participants were postmenopausal. The FDA prescribing information states that serum levels of estrone, estradiol, and testosterone increase slightly but does not characterize what those rises would look like on top of the much higher baseline levels a 32-year-old with normal ovarian function carries.

In a premenopausal woman, the same nightly insertion would add DHEA to a system that is already converting endogenous DHEA-S (circulating at levels 10 to 20 times higher than postmenopausal values) into local sex steroids. The additive pharmacological effect is genuinely unknown. It may be negligible for local vaginal tissue if receptor saturation has already occurred. It could theoretically produce unexpected androgenic effects at a systemic level. No published data answers this question definitively.

A practical clinical framework for evaluating whether Intrarosa is appropriate for a woman in her 30s should move through four gates:

1. Is she physiologically hypoestrogenic? (POI, surgical menopause, chemotherapy, GnRH suppression therapy confirmed by FSH and estradiol levels)
2. Have other causes of dryness been excluded? (Contraception-related, postpartum, medication-induced, autoimmune, thyroid)
3. Is she pregnant, planning pregnancy, or breastfeeding? (If yes, stop here; prasterone is not appropriate)
4. Has her oncology or subspecialty team cleared local hormonal therapy? (Essential for cancer survivors)

Only a woman who clears gates 1, 2, and 3, and gate 4 where applicable, is a reasonable candidate for off-label prasterone use in her 30s.

Pregnancy and Lactation: The Non-Negotiable Safety Section

Prasterone is contraindicated in pregnancy. This is not a soft warning. DHEA is a direct precursor to both androgens and estrogens. Exogenous androgen exposure during the first trimester carries risk of virilization of a female fetus. The FDA label carries no formal pregnancy category under the post-2015 labeling system but includes language directing that prasterone should not be used during pregnancy. Animal reproductive studies showed adverse effects at exposures exceeding clinical doses; human data are absent because the drug should never be used in pregnancy.

Contraception Requirement

Any woman in her 30s who retains any ovarian function, even reduced function from chemotherapy or POI with intermittent follicular activity, must use reliable contraception while using Intrarosa if pregnancy would be harmful or unintended. POI is not the same as sterility: ACOG notes that approximately 5-10% of women with POI conceive spontaneously. A woman using prasterone who becomes pregnant should stop the medication immediately and contact her clinician.

Barrier methods and non-hormonal IUDs (copper IUD) avoid the added complexity of hormonal contraception interacting with exogenous DHEA. If a hormonal method is preferred, the conversation should include the effect of combined oral contraceptives on SHBG and free testosterone, since DHEA can convert to testosterone locally.

Lactation

No human lactation data exist for vaginally administered prasterone. DHEA does transfer into milk in animal models. Because neonatal androgen exposure during a sensitive developmental window carries theoretical risk, the conservative position is to avoid prasterone while breastfeeding. Vaginal moisturizers (non-hormonal) and low-dose vaginal estrogen creams are better-studied alternatives for postpartum dyspareunia in non-breastfeeding or breastfeeding women who need something.

Trying to Conceive

If you are actively trying to conceive, prasterone vaginal inserts are not appropriate. The contraindication in pregnancy means you need a pregnancy-safe solution for the same window when conception is possible. Discuss non-hormonal lubricants and moisturizers, which The Menopause Society recommends as first-line for mild dryness, with your clinician.

Conditions Common in Your 30s That Intersect With Prasterone Use

PCOS

PCOS affects 6-13% of women of reproductive age globally. Women with PCOS have elevated androgens. DHEA-S is elevated in approximately 20-30% of PCOS cases. Adding exogenous DHEA, even vaginally, in a woman with already-elevated DHEA-S raises a theoretical concern about further androgenic stimulation, although no trial has tested this directly. Vaginal dryness in PCOS is not caused by estrogen deficiency in typical reproductive-age women; other contributors, including hormonal contraception used to manage PCOS symptoms, are far more likely culprits.

Endometriosis

Women with endometriosis frequently use GnRH agonist or antagonist therapy, which creates the hypoestrogenic environment where prasterone becomes relevant. For this group, prasterone represents one of several vaginal options to manage the genitourinary side effects of medically induced menopause. A 2022 ACOG Practice Bulletin on endometriosis supports add-back hormonal therapy during GnRH agonist treatment to reduce hypoestrogenic symptoms; prasterone could logically fill the vaginal symptom component of that add-back strategy, though it is not explicitly named.

Breast Cancer in Your 30s

Breast cancer before 40 is uncommon but not rare, accounting for roughly 4% of all breast cancer diagnoses. Women receiving aromatase inhibitors, ovarian suppression with GnRH agonists plus aromatase inhibitor, or chemotherapy face severe VVA. For women with hormone-receptor-negative breast cancer, local vaginal therapies are generally considered safer. For hormone-receptor-positive disease, the safety of any locally absorbed estrogen or estrogen precursor, including prasterone, requires individual oncology sign-off. A 2022 ACOG Clinical Practice Bulletin acknowledged the ongoing uncertainty around vaginal hormone therapy in hormone-sensitive cancer survivors and advised shared decision-making.

Thyroid Disease

Autoimmune thyroid disease (Hashimoto thyroiditis, Graves disease) peaks in women between 30 and 50. Hypothyroidism can independently cause decreased vaginal lubrication and sexual dysfunction. Before attributing symptoms to a hormone-driven VVA diagnosis, confirm TSH is optimized. If thyroid disease is the primary driver, Intrarosa will not solve the problem.

Who This Is Right For, and Who It Is Not

May Be Appropriate (in your 30s)

• Women with confirmed POI (FSH persistently above 40 mIU/mL, estradiol below 20 pg/mL) who have troublesome dyspareunia or VVA not adequately managed by moisturizers and lubricants
• Women post-bilateral oophorectomy with symptomatic VVA who cannot or choose not to use systemic estrogen
• Women on GnRH agonist or antagonist therapy for endometriosis or fibroids with symptomatic VVA, in consultation with their prescribing specialist
• Breast cancer survivors (after oncology clearance, particularly hormone-receptor-negative disease) with treatment-induced ovarian suppression

Not Appropriate (in your 30s)

• Women with normal ovarian function and estradiol levels who have dryness from other causes (contraception, SSRI use, postpartum, Sjögren)
• Any woman who is pregnant, trying to conceive in the near term, or breastfeeding
• Women with PCOS and elevated DHEA-S without a confirmed hypoestrogenic state
• Women who have not had thyroid function, contraception effects, and medication contributors evaluated first

"Genitourinary syndrome of menopause is the preferred term for the constellation of vulvovaginal atrophy symptoms, and its management must be matched to the underlying hormonal cause, not just the symptom," notes The Menopause Society's 2023 position statement on genitourinary syndrome of menopause. This principle applies directly to younger women: symptom alone does not justify the diagnosis.

Dosing, Administration, and Practical Details

The FDA-approved dose is one 6.5 mg prasterone vaginal insert nightly. No alternative dose has been approved, and no dose adjustment is studied for younger women or women with residual ovarian function.

How to Insert

The insert comes with a single-use applicator. It is placed in the vagina at bedtime, similar to a vaginal estrogen tablet. Lying down after insertion reduces the chance of the insert slipping out before it dissolves.

What to Expect

• Vaginal discharge: A white discharge from the dissolving suppository base is common and normal.
• Onset: Phase 3 trial data showed statistically significant improvement in the most bothersome symptom by 12 weeks, with some women noticing change as early as 4 weeks.
• Duration of use: No maximum duration has been established in trials; the 52-week open-label extension of the Phase 3 program showed continued benefit without new safety signals in the postmenopausal population studied.

Cost and Access

Intrarosa is not generic as of early 2025. Monthly cost without insurance ranges from approximately $250 to $380. Manufacturer savings programs exist. For women in their 30s using it off-label, insurance coverage is unlikely without a prior authorization documenting the underlying hypoestrogenic condition.

The Evidence Gap: What We Do Not Know

Women in their 30s have been systematically excluded from prasterone trials. This is not a regulatory or clinical oversight. It reflects the drug's approved indication: menopause-related VVA in postmenopausal women. Every piece of efficacy data you will find, the AMELIA trial, the Phase 2 dose-ranging studies, the 52-week open-label extension, enrolled women with FSH above 40 mIU/mL and at least 12 months of amenorrhea.

What we do not know for younger hypoestrogenic women includes:

• Whether 6.5 mg nightly is the right dose when DHEA-S starting levels may be higher than in natural menopause
• Whether systemic absorption differs meaningfully by age or residual ovarian function
• Long-term safety signals specific to women using this drug for decades rather than years
• Whether prasterone affects follicular development or fertility in women with partial ovarian function

As Labrie and colleagues noted in a 2015 review in the Journal of Steroid Biochemistry and Molecular Biology, the intracrinology model assumes that peripheral tissues regulate their own steroid production independently. Whether this assumption holds in younger women with active hypothalamic-pituitary-ovarian axis activity has not been formally tested.

WomanRx asked Dr. Rachel Goldberg, MD (OB-GYN and reproductive endocrinologist), to put this directly: "When a woman in her 30s comes to me with vaginal dryness and pain with sex, my first job is to find out why her estrogen is low, because in this age group it is rarely natural menopause. The diagnosis drives the treatment. Prasterone may be a reasonable option for some of my surgically menopausal or POI patients who prefer a non-systemic route, but I would not reach for it as a first line for any 30-something without a confirmed hypoestrogenic state."

Alternatives Worth Knowing About

If prasterone is not the right fit, these options have evidence specifically in younger or premenopausal hypoestrogenic women or in women with medication-induced dryness:

• Vaginal estrogen creams, tablets, or rings (low-dose): The lowest-effective-dose vaginal estrogen formulations (0.01% estradiol cream, 10 mcg estradiol vaginal tablet) produce minimal systemic absorption and remain first-line for VVA in women who can use estrogen. ACOG Practice Bulletin 141 supports vaginal estrogen as safe and effective for GSM.
• Ospemifene: An oral SERM approved for dyspareunia. Not appropriate in premenopausal women with intact ovarian function due to SERM effects on the reproductive axis, and contraindicated in pregnancy.
• Non-hormonal vaginal moisturizers: Polycarbophil and hyaluronic acid-based products used regularly (every 2-3 days) reduce vaginal pH and improve tissue hydration. No hormonal activity, safe in pregnancy and lactation, appropriate for any life stage.
• Lubricants: Water-based or silicone-based lubricants used at the time of intercourse address dyspareunia directly without any hormonal effect. Appropriate as a first step while underlying causes are being evaluated.